Abstract | OBJECTIVE: METHODS: This study was a prospective, open-label, single-arm study of adult patients with moderate-to-severe chronic plaque psoriasis who had suboptimal response after ≥24 weeks of treatment with ixekizumab (residual 3–8% body surface area [BSA] involvement). All patients continued treatment with ixekizumab and received once-daily Cal/BD foam for 4 weeks, followed by every other day for weeks 8 to 12. The primary endpoint was treat-to-target BSA ≤1% at week 4. Additional endpoints included the Physician’s Global Assessment ( PGA) score, PGA×BSA, and the patient-reported Dermatology Life Quality Index (DLQI). Safety evaluations included assessments of adverse events (AEs) and local skin reactions. RESULTS: Among 25 enrolled patients, 36% were female, and the mean age was 50 years. After 4 weeks of daily Cal/BD foam, 56% of patients achieved the treat-to-target goal of ≤1% BSA. Mean % BSA involvement, mean PGA score, and composite PGA×BSA score decreased 4 weeks after the addition of Cal/BD foam. Improvements in disease severity outcomes were maintained after reducing Cal/BD dosing frequency. Cal/BD was generally safe and well-tolerated, with no serious AEs reported. CONCLUSION: In real-world clinical practice, for patients with moderate-to-severe plaque psoriasis who had residual plaques following ≥24 weeks of ixekizumab monotherapy, adjunctive treatment with Cal/BD foam was associated with notable and sustained improvements in disease control. J Drugs Dermatol. 2022;21(3): 235-240. doi:10.36849/JDD.6396.
|
Authors | Jerry Bagel, Elise Nelson |
Journal | Journal of drugs in dermatology : JDD
(J Drugs Dermatol)
Vol. 21
Issue 3
Pg. 235-240
(Mar 01 2022)
ISSN: 1545-9616 [Print] United States |
PMID | 35254755
(Publication Type: Journal Article)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Dermatologic Agents
- Drug Combinations
- calcipotriene
- betamethasone-17,21-dipropionate
- Betamethasone
- ixekizumab
- Calcitriol
|
Topics |
- Adult
- Antibodies, Monoclonal, Humanized
- Betamethasone
(analogs & derivatives)
- Calcitriol
(analogs & derivatives)
- Dermatologic Agents
(adverse effects)
- Drug Combinations
- Female
- Humans
- Middle Aged
- Prospective Studies
- Psoriasis
(drug therapy)
- Treatment Outcome
|